Cancer Type: Malignant Hematology
Study Type: Treatment
Phase: Phase I/II
Principal Investigator: Chavez, Julio
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
The trial is an open-label, multi-center safety trial of epcoritamab GEN3013 (DuoBody®-CD3xCD20). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH) and an expansion part phase 2a. The purpose of the escalation part of the trial is to determine the maximum tolerated dose and the recommended phase 2 dose (RP2D) as well as to establish the safety profile of epcoritamab GEN3013 (DuoBody®-CD3xCD20) in patients with relapsed, progressive or refractory B-Cell Lymphoma. In the expansion part additional patients will be treated with epcoritamab with the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab.
Dose Escalation Objectives: Primary: -Determine maximum tolerated dose and recommended phase 2 dose Secondary: -Establish tolerability of GEN3013 -Establish PK profile after single and multiple doses -Evaluate immunogenicity -Evaluate anti-lymphoma activity Exploratory: -To evaluate biomarkers predictive of clinical response to GEN3013 -To evaluate pharmacodynamic markers linked to the mechanism of action of GEN3013 Expansion Objectives: Primary -To evaluate clinical efficacy as determined by Lugano criteria Secondary: -To further evaluate clinical efficacy as determined by Lugano criteria -To evaluate anti-lymphoma activity as determined by Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) -To further evaluate clinical efficacy -To evaluate MRD status as a clinical efficacy endpoint -To evaluate safety and tolerability GEN3013 -To evaluate the PK and immunogenicity of GEN3013 -To evaluate patient-reported outcomes (PROs) related to lymphoma symptoms Exploratory: -To evaluate biomarkers predictive of clinical response to GEN3013 -To evaluate pharmacodynamic markers linked to the mechanism of action of GEN3013 -To evaluate PROs related to well-being and general health status
Main Inclusion Criteria Escalation Part
Expansion Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
A secure website for patients to access their medical care at Moffitt.
An online resource for referring physicians and their staff.
For Moffitt faculty & staff members to access MoffittNet applications.
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday